5.15
1.58%
+0.08
Affimed N.V. stock is currently priced at $5.15, with a 24-hour trading volume of 63,710.
It has seen a +1.58% increased in the last 24 hours and a +0.98% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.14 pivot point. If it approaches the $5.22 resistance level, significant changes may occur.
Affimed N.V. Stock (AFMD) Financials Data
Affimed N.V. (AFMD) Revenue 2024
AFMD reported a revenue (TTM) of $19.91 million for the quarter ending September 30, 2023, a -54.33% decline year-over-year.
Affimed N.V. (AFMD) Net Income 2024
AFMD net income (TTM) was -$127.11 million for the quarter ending September 30, 2023, a -54.28% decrease year-over-year.
Affimed N.V. (AFMD) Cash Flow 2024
AFMD recorded a free cash flow (TTM) of -$132.44 million for the quarter ending September 30, 2023, a -19.90% decrease year-over-year.
Affimed N.V. (AFMD) Earnings per Share 2024
AFMD earnings per share (TTM) was -$8.428 for the quarter ending September 30, 2023, a -35.13% decline year-over-year.
Affimed N.V. Stock (AFMD) Latest News
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks Investment Research
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
Zacks Investment Research
Affimed Reports 2023 Financial Results and Operational Progress
GlobeNewswire Inc.
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
GlobeNewswire Inc.
Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
About Affimed N.V.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company's products include AFM24, a NK-cell bispecific antibody targets EGFR-wild type represents a validated antigen expressed by various solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its products also comprise AFM11, a T cell TandAb, which is in Phase 1 clinical trial in patients with relapsed CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Cap:
|
Volume (24h):